Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

Highly selective inhibitors of the inducible cyclooxygenase‐2 enzyme (coxibs) have been associated with less gastrotoxicity than nonselective NSAIDs in clinical studies.

[1]  C. Hawkey,et al.  Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. , 2000, Arthritis and rheumatism.

[2]  J. Bolognese,et al.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. , 1999, JAMA.

[3]  L. Laine,et al.  A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. , 1999, Gastroenterology.

[4]  H Perrier,et al.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  C. Hawkey,et al.  Helicobacter pylori, NSAIDs and cognitive dissonance , 1999, Alimentary pharmacology & therapeutics.

[6]  A. Barkun,et al.  Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. , 1999, The New England journal of medicine.

[7]  D. Riendeau,et al.  Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model , 1999, Clinical pharmacology and therapeutics.

[8]  Á. Lanas,et al.  Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study , 1998, The Lancet.

[9]  C. Hawkey,et al.  Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. , 1998, British journal of rheumatology.

[10]  M. Kimmey,et al.  Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[11]  A. Barkun,et al.  Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs , 1998 .

[12]  C. Hawkey,et al.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. , 1998, The New England journal of medicine.

[13]  P. Netzer,et al.  Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in rats , 1998, British journal of pharmacology.

[14]  M. Kasuga,et al.  Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. , 1997, Gastroenterology.

[15]  K. Seibert,et al.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Graham,et al.  Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. , 1994, Gastrointestinal endoscopy.

[17]  H. Jick,et al.  Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.

[18]  E. Remmers,et al.  Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. , 1994, The Journal of clinical investigation.

[19]  D. Graham,et al.  Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. , 1994, Human pathology.

[20]  S. Gabriel,et al.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. , 1991, Annals of internal medicine.

[21]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[22]  W. Ray,et al.  Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. , 1991, Annals of internal medicine.

[23]  K. Seibert,et al.  The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. , 1990, The Journal of biological chemistry.

[24]  C. Hawkey.  Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance. , 1999, Alimentary pharmacology & therapeutics.

[25]  C. Hawkey,et al.  Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. , 1998, Lancet.